Curbside Consults: Improving Long-term Post-Vitrectomy Outcomes With an Eye on Inflammation

Author(s)/Faculty: Sumit Sharma, MD; Rishi P. Singh, MD
Release Date: 11/30/2021Expiration Date: 11/29/2022
Credit Type: CME / CME with ABO Continuing Certification Number of Credits: 0.25
Content Type: LectureProvider:
Uveitis—inflammation of the uveal track—is believed to be responsible for about 10% of blindness in the United States. Approximately 80% of uveitis is of noninfectious etiology. Therapy for patients with uveitis is determined based on the severity and location of the inflammation. To this end, 4 subtypes of uveitis are recognized, according to location: anterior, intermediate, posterior, and panuveitis. Posterior uveitis may affect the retina and/or the optic nerve and may lead to permanent loss of vision. It can result from noninfectious uveitis, postsurgical inflammation, or inflammation as a result of a nonautoimmune response. Hence, it encompasses not only ocular sequelae but a large spectrum of associated systemic diseases. Corticosteroids are a highly effective drug class for the treatment of ocular inflammation but are associated with adverse effects such as cataract, increased intraocular pressure, and adrenal insufficiency. New delivery systems have been developed that administer therapeutic levels of steroids for weeks or months, with reduced side effect profiles and additional benefits such as improved adherence to treatment regimens and greater patient satisfaction. In this case-based series, expert faculty will explore how sustained reduction of inflammation in the eye due to noninfectious uveitis and its subtypes can improve long-term outcomes, how the sustained delivery of corticosteroids can improve post-surgical outcomes in patients undergoing retinal surgery, as well as the spectrum of disease referred to as posterior uveitis.